Treatment of Chronic Atrial Fibrillation

Introduction to Treatment Strategies

The European Society of Cardiology recommends rate control with anticoagulation as the initial strategy for most patients with chronic atrial fibrillation, using beta-blockers or non-dihydropyridine calcium channel blockers as first-line agents, combined with direct oral anticoagulants for stroke prevention 1, 2, 3

The American Heart Association suggests that all patients with chronic atrial fibrillation require anticoagulation unless they have lone atrial fibrillation or contraindications 3
Direct oral anticoagulants, such as apixaban, rivaroxaban, dabigatran, or edoxaban, are recommended over warfarin due to superior safety profiles and at least equivalent efficacy for stroke prevention 1, 3
Apixaban is ranked highest for efficacy and safety outcomes, with demonstrated superiority over warfarin and significantly less major bleeding 3

The American College of Cardiology recommends rate control with chronic anticoagulation for the majority of patients with chronic atrial fibrillation, as rhythm control has not been shown superior in reducing morbidity and mortality 2
For patients with left ventricular ejection fraction greater than 40%, beta-blockers, diltiazem, or verapamil are recommended as first-choice drugs for rate control 1, 2
For patients with left ventricular ejection fraction less than or equal to 40%, beta-blockers and/or digoxin are recommended 1

Rhythm control is appropriate when based on patient symptoms, exercise tolerance, and patient preference, particularly in patients whose quality of life is compromised by atrial fibrillation despite adequate rate control 2
For selected patients requiring rhythm maintenance, the recommended pharmacologic agents are amiodarone, disopyramide, propafenone, and sotalol, with choice depending on specific risk of side effects based on patient characteristics 2

For patients with heart failure with preserved ejection fraction, beta-blocker or non-dihydropyridine calcium channel antagonist is recommended for persistent or permanent atrial fibrillation 4, 5
For patients with heart failure with reduced ejection fraction, IV digoxin or amiodarone is recommended to acutely control heart rate in the acute setting with atrial fibrillation and rapid ventricular response 4, 5

Regularly assess renal function and periodically reassess bleeding risk in patients on direct oral anticoagulants 3
Check international normalized ratio weekly during initiation and monthly once stable in patients on warfarin 3